Claims for Patent: 11,944,595

Summary for Patent: 11,944,595

Title:	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Abstract:	A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US18/144,528
Patent Claims:	1. A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject comprising: administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin. 2. The method of claim 1, wherein the composition is in a form of a tablet or a capsule. 3. The method of claim 1, wherein the composition is in a form of a liquid dose, a gel, or a powder. 4. The method of claim 1, wherein the statin is chosen from atorvastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, simvastatin, pravastatin, a pharmaceutically acceptable salt thereof, and any combination thereof. 5. The method of claim 1, wherein the subject is from about 35 to about 85 years of age. 6. The method of claim 1, wherein the MI is a non-stent related acute myocardial infarction. 7. The method of claim 1, wherein the subject is administered the composition daily for at least 24 months. 8. The method of claim 1, wherein the subject is administered the composition daily for at least 36 months. 9. The method of claim 1, wherein the subject is administered the composition daily for at least 44 months. 10. A method for reducing acute myocardial infarction risk in a subject comprising: administering, orally once per day to the subject, a composition comprising no more than about 0.6 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii). 11. The method of claim 10, wherein the composition is in a form of a tablet or capsule. 12. The method of claim 10, wherein the composition is in a form of a liquid dose, gel, or powder. 13. The method of claim 10, wherein the subject has at least one history of a previous diagnosis of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty. 14. The method of claim 10, wherein the subject is from about 35 to about 85 years of age. 15. The method of claim 10, wherein the acute myocardial infarction is non-stent related acute myocardial infarction. 16. The method of claim 10, wherein the subject is administered the composition daily for at least 24 months. 17. The method of claim 10, wherein the subject is administered the composition daily for at least 36 months. 18. The method of claim 10, wherein the subject is administered the composition daily for at least 44 months.